Covington Investment Advisors Has Decreased Its Merck & Co New (MRK) Position by $2.03 Million; Cvs Health (CVS) Shareholder Tekla Capital Management Has Cut Its Stake by $3.27 Million

April 25, 2018 - By Jacob Smith

CVS Health Corporation (NYSE:CVS) Logo

Covington Investment Advisors Inc decreased its stake in Merck & Co Inc New (MRK) by 76.08% based on its latest 2017Q4 regulatory filing with the SEC. Covington Investment Advisors Inc sold 36,210 shares as the company’s stock declined 4.63% with the market. The institutional investor held 11,384 shares of the health care company at the end of 2017Q4, valued at $641,000, down from 47,594 at the end of the previous reported quarter. Covington Investment Advisors Inc who had been investing in Merck & Co Inc New for a number of months, seems to be less bullish one the $160.10B market cap company. The stock decreased 1.06% or $0.635 during the last trading session, reaching $59.455. About 7.09 million shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since April 25, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Tekla Capital Management Llc decreased its stake in Cvs Health Corporation (CVS) by 11.02% based on its latest 2017Q4 regulatory filing with the SEC. Tekla Capital Management Llc sold 45,370 shares as the company’s stock declined 17.45% with the market. The institutional investor held 366,521 shares of the medical and nursing services company at the end of 2017Q4, valued at $26.57M, down from 411,891 at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Cvs Health Corporation for a number of months, seems to be less bullish one the $68.82B market cap company. The stock increased 1.66% or $1.105 during the last trading session, reaching $67.705. About 5.76M shares traded. CVS Health Corporation (NYSE:CVS) has declined 22.81% since April 25, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

Since February 16, 2018, it had 0 insider buys, and 1 sale for $1.42 million activity.

Tekla Capital Management Llc, which manages about $1.06 billion and $2.59 billion US Long portfolio, upped its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 14,406 shares to 38,706 shares, valued at $1.99M in 2017Q4, according to the filing. It also increased its holding in New Senior Investment Group Inc. (NYSE:SNR) by 315,922 shares in the quarter, for a total of 883,919 shares, and has risen its stake in Pfizer Inc. (NYSE:PFE).

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 76 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird on Thursday, January 4 with “Hold”. Needham maintained the stock with “Hold” rating in Friday, September 8 report. The firm has “Buy” rating given on Monday, December 4 by Needham. Leerink Swann maintained the stock with “Buy” rating in Monday, January 8 report. The firm has “Buy” rating by Tigress Financial given on Tuesday, December 26. Raymond James upgraded the stock to “Buy” rating in Thursday, January 4 report. On Friday, February 9 the stock rating was maintained by Leerink Swann with “Outperform”. The rating was upgraded by Vetr on Monday, August 24 to “Buy”. On Wednesday, October 18 the stock rating was maintained by Jefferies with “Hold”. The firm has “Buy” rating given on Tuesday, January 2 by Needham.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on May, 2 before the open. They expect $1.40 earnings per share, up 19.66% or $0.23 from last year’s $1.17 per share. CVS’s profit will be $1.42 billion for 12.09 P/E if the $1.40 EPS becomes a reality. After $1.92 actual earnings per share reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts -27.08% negative EPS growth.

Investors sentiment decreased to 0.72 in 2017 Q4. Its down 0.16, from 0.88 in 2017Q3. It is negative, as 115 investors sold CVS shares while 600 reduced holdings. 134 funds opened positions while 380 raised stakes. 815.59 million shares or 1.76% more from 801.45 million shares in 2017Q3 were reported. Griffin Asset Mngmt invested in 0.12% or 9,479 shares. Washington Communication holds 0.88% in CVS Health Corporation (NYSE:CVS) or 216,023 shares. Capital One National Association holds 30,054 shares. Hsbc Holdg Plc holds 0.28% of its portfolio in CVS Health Corporation (NYSE:CVS) for 2.66M shares. Cetera Advisor Netwr Ltd Llc owns 19,955 shares. Carret Asset Mgmt Limited Company owns 95,319 shares. Cubic Asset Mngmt Ltd Liability stated it has 1.51% of its portfolio in CVS Health Corporation (NYSE:CVS). Essex Management Limited Liability Com, a Massachusetts-based fund reported 11,062 shares. M&R Mgmt Inc owns 61,354 shares. Beck Mack Oliver Ltd Llc invested in 0.03% or 13,296 shares. Kayne Anderson Rudnick Inv Mngmt Llc has invested 0.03% in CVS Health Corporation (NYSE:CVS). Umb Bank N A Mo stated it has 105,584 shares. Cypress Asset Management Tx, Texas-based fund reported 19,460 shares. Nuwave Invest Mgmt Ltd Llc reported 339 shares or 0.03% of all its holdings. Charter reported 0.17% stake.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.12, from 1.06 in 2017Q3. It is negative, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. Chesley Taft & Assocs Ltd Co stated it has 81,056 shares. Checchi Advisers Limited Co, a California-based fund reported 24,981 shares. Hennessy Advsr stated it has 38,950 shares. Cwm Ltd Com holds 97,003 shares or 0.24% of its portfolio. Davis R M Inc holds 0.55% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 249,018 shares. Sabal Tru invested 0.04% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Pacific Global Investment Mngmt owns 0.27% invested in Merck & Co., Inc. (NYSE:MRK) for 21,712 shares. The New York-based Shufro Rose And Co Lc has invested 0.11% in Merck & Co., Inc. (NYSE:MRK). Nippon Life Insur has 0.67% invested in Merck & Co., Inc. (NYSE:MRK) for 567,400 shares. Bryn Mawr Trust holds 185,424 shares or 0.57% of its portfolio. Hgk Asset Management has 0.05% invested in Merck & Co., Inc. (NYSE:MRK) for 6,000 shares. Mason Street Advsr Lc holds 0.5% in Merck & Co., Inc. (NYSE:MRK) or 380,986 shares. Banced holds 5,126 shares or 0.48% of its portfolio. Pennsylvania-based Barton Investment Mgmt has invested 0.13% in Merck & Co., Inc. (NYSE:MRK). Finance Advisory invested in 13,528 shares or 0.2% of the stock.

Covington Investment Advisors Inc, which manages about $239.59M and $292.13 million US Long portfolio, upped its stake in Ishares U S Etf Tr by 46,375 shares to 305,407 shares, valued at $8.07 million in 2017Q4, according to the filing.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>